Comparative analysis of the effectiveness of inhibitor-protected cephalosporins fortified with basic antibiotic
https://doi.org/10.21508/1027-4065-2021-66-5-172-175
Abstract
Inhibitor-protected cephalosporins are an important tool against hospital infections caused by extended spectrum β-lactamase producers. At the same time, the relative deficiency of the basic antibiotic in combination with the β-lactamase inhibitor sulbactam (1: 1) may be associated with the risk of therapeutic failure.
Objective. To compare therapeutic effect of various regimens for prescribing inhibitor-protected cephalosporins in children with severe bacterial infection.
Children characteristics and research methods. The authors compared clinical efficacy of cefotaxime / sulbactam, cefoperazone / sulbactam, cefepime / sulbactam at maximum doses and main component-fortified-cefepime / sulbactam. The study included 92 patients aged from 2 months to 12 years with appendicular peritonitis, acute purulent osteomyelitis, complicated hospital infections of the lower respiratory tract, exacerbation of chronic purulent otitis media and chronic urinary tract infections. It was found that inhibitor-protected cephalosporins with a 1: 1 ratio of components more often necessitated a change in therapy. The use of drugs initially containing a basic antibiotic in a high dose (component ratio 2:1) or additionally fortified with a basic antibiotic demonstrated a higher therapeutic efficacy.
About the Author
R. N. Mamleev
Children’s Republican Clinical Hospital; Kazan State Medical University
Russian Federation
Russian Federation
Kazan
References
1. Zhivich A. Fighting bacterial resistance: approaches, challenges, and opportunities in the search for new antibiotics. Part 1. Antibiotics used in clinical practice: mechanisms of action and the development of bacterial resistance. Microbiol Independ Res J (MIRJ) 2017; 4(1): 31–51. DOI: 10.18527/2500-2236-2017-4-1-31-51
2. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance/ Ссылка активна на 19.06.2021
3. Mohr K.I. History of Antibiotics Research. Curr Top Microbiol Immunol 2016; 398: 237–272. DOI: 10.1007/82_2016_499
4. Williams J.D. Beta-lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone. Clin Infect Dis 1997; 24(3): 494–497. DOI: 10.1093/clinids/24.3.494
5. Strachunskij L.S. Extended-spectrum β-lactamases – a rapidly growing and poorly understood threat. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya 2005; 7(1): 92–96. (in Russ.)
6. Korobova А.G., Klyasova G.А. Enterobacteriaceae with extended spectrum β-lactamase production: sources of infection and the importance of colonization of the intestinal mucosa in patients with hemoblastosis. Gematologiya i transfuziologiya 2018; 63(1): 174–183. (in Russ.)
7. The Sanford Guide to Antimicrobial Therapy. D. Gilbert, G. Chambers, J. Eliopoulos, M. Saag, D. Black, D. Friedman et al. (eds). Second Russian edition. Transl. from English V.B. Beloborodov, A.I. Mazus. Moscow: GRANAT, 2016; 688. (in Russ.)
Review
For citations:
Mamleev R.N. Comparative analysis of the effectiveness of inhibitor-protected cephalosporins fortified with basic antibiotic. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2021;66(5):172-175. (In Russ.) https://doi.org/10.21508/1027-4065-2021-66-5-172-175
Views:
670
Email this article 